Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Zentalis Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 3.14 · gapped above the open, never looked back. High/low 3.38 at 9:30 am ET, 3.14 at 3:45 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“GSK supplied niraparib for use in the collaboration, at no cost to us.”
FILING10-K0001725160-26-000014cik 0001725160
“We previously had development collaborations for azenosertib with Pfizer Inc., GSK plc, and Dana-Farber Cancer Institute.”
FILING10-K0001725160-26-000014cik 0001725160
“We previously had development collaborations for azenosertib with Pfizer Inc., GSK plc, and Dana-Farber Cancer Institute.”
FILING10-K0001725160-26-000014cik 0001725160
“In December 2014, our wholly owned subsidiary, Zeno Pharmaceuticals, Inc., entered into the Recurium Agreement with Recurium IP Holdings, LLC, or Recurium IP, which was subsequently amended, under which Zeno Pharmaceuticals, Inc. was granted an exclusive worldwide license to certain intellectual property rights owned or controlled by Recurium IP to develop and commercialize pharmaceutical products for the treatment or prevention of disease, other than for providing pain relief.”
FILING10-K0001725160-26-000014cik 0001725160
“In May 2021, the Company entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, as sales agent (the "Sales Agreement"), pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $75.0 million in "at-the-market" offerings, or the ATM, under the Company's Registration Statement on Form S-3 (File No. 333-286122) filed with the SEC on March 26, 2025.”
FILING10-K0001725160-26-000014cik 0001725160
“In January 2024, we entered into an exclusive, worldwide license agreement with Immunome, or the Immunome License Agreement, under which Immunome licensed from us ZPC-21 (now known as IM-1021), a preclinical ROR1 ADC with best-in-class potential, and our proprietary ADC platform technology, or the ADC Assets.”
FILING10-K0001725160-26-000014cik 0001725160
Watchlist prices, news filtered to it, and its next report on your desk.
Zentalis Pharmaceuticals, Inc. has 5 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Zentalis Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
ZNTL (Zentalis Pharmaceuticals, Inc.) has 5 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: IMNM −0.07%, in healthcare.